Company: ERAS
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103868
Chunk: 36

Company: Erasca, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 36
---
 Code of Business Conduct and Ethics applies to all of our employees, officers and directors, and requires the highest standards of business ethics. The Code of Business Conduct and Ethics and other corporate governance documents are located in the “Corporate Governance” section of the “Investors” page of our website located at www.erasca.com. |

| • |     | Inclusive clinical trial participation:We intend to make clinical trials of our product candidates more accessible to all patient populations and plan to partner with others who are like-minded in this regard. |

| • |     | Drug access program:If our products become commercially available,we intend to pursue initiatives to provide patients with access to such drugs, including through patient assistance programs andcompassionate use programs. |

23

Executive and Director Compensation This section discusses the material components of the executive compensation program for our executive officers who are named in the “Summary compensation table” below, whom we refer to as our named executive officers or NEOs. For 2024, our NEOs and their positions were as follows:

| • |     | Jonathan E. Lim, M.D., Chairman, Chief Executive Officer, andCo-Founder; |

| • |     | David M. Chacko, M.D., Chief Financial Officer and Chief Business Officer; and |

| • |     | Shannon R. Morris, M.D., Ph.D., Chief Medical Officer. |

Summary compensation table The following table presents summary information regarding the total compensation that was awarded to, earned by or paid to our NEOs for services rendered during the years ended December 31, 2024 and 2023.

| Name and                                           
 principal Position                                 |     | Year |      |     | Salary 
 ($)    |         |     | Bonus 
 ($)   |   |     | Stock  
 awards 
 ($)    |   |     | Option 
 awards 
 ($)(1) |           |     | Non-equity     
 incentive plan 
 compensation   
 ($)(2)         |         |     | All other    
 compensation 
 ($)(3)       |        |     | Total 
 ($)   |           |
| Jonathan E. Lim, M.D.                              |     |      | 2024 |     |        | 644,600 |     |       | — |     |        | — |     |        | 2,794,308 |     |                | 444,774 |     |              | 10,350 |     |       | 3,894,032 |
| Chairman, Chief Executive